Cargando…

Depsipeptides Targeting Tumor Cells: Milestones from In Vitro to Clinical Trials

Cancer is currently considered one of the most threatening diseases worldwide. Diet could be one of the factors that can be enhanced to comprehensively address a cancer patient’s condition. Unfortunately, most molecules capable of targeting cancer cells are found in uncommon food sources. Among them...

Descripción completa

Detalles Bibliográficos
Autores principales: Trinidad-Calderón, Plinio A., Varela-Chinchilla, Carlos Daniel, García-Lara, Silverio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864405/
https://www.ncbi.nlm.nih.gov/pubmed/36677728
http://dx.doi.org/10.3390/molecules28020670
_version_ 1784875576440389632
author Trinidad-Calderón, Plinio A.
Varela-Chinchilla, Carlos Daniel
García-Lara, Silverio
author_facet Trinidad-Calderón, Plinio A.
Varela-Chinchilla, Carlos Daniel
García-Lara, Silverio
author_sort Trinidad-Calderón, Plinio A.
collection PubMed
description Cancer is currently considered one of the most threatening diseases worldwide. Diet could be one of the factors that can be enhanced to comprehensively address a cancer patient’s condition. Unfortunately, most molecules capable of targeting cancer cells are found in uncommon food sources. Among them, depsipeptides have emerged as one of the most reliable choices for cancer treatment. These cyclic amino acid oligomers, with one or more subunits replaced by a hydroxylated carboxylic acid resulting in one lactone bond in a core ring, have broadly proven their cancer-targeting efficacy, some even reaching clinical trials and being commercialized as “anticancer” drugs. This review aimed to describe these depsipeptides, their reported amino acid sequences, determined structure, and the specific mechanism by which they target tumor cells including apoptosis, oncosis, and elastase inhibition, among others. Furthermore, we have delved into state-of-the-art in vivo and clinical trials, current methods for purification and synthesis, and the recognized disadvantages of these molecules. The information collated in this review can help researchers decide whether these molecules should be incorporated into functional foods in the near future.
format Online
Article
Text
id pubmed-9864405
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98644052023-01-22 Depsipeptides Targeting Tumor Cells: Milestones from In Vitro to Clinical Trials Trinidad-Calderón, Plinio A. Varela-Chinchilla, Carlos Daniel García-Lara, Silverio Molecules Review Cancer is currently considered one of the most threatening diseases worldwide. Diet could be one of the factors that can be enhanced to comprehensively address a cancer patient’s condition. Unfortunately, most molecules capable of targeting cancer cells are found in uncommon food sources. Among them, depsipeptides have emerged as one of the most reliable choices for cancer treatment. These cyclic amino acid oligomers, with one or more subunits replaced by a hydroxylated carboxylic acid resulting in one lactone bond in a core ring, have broadly proven their cancer-targeting efficacy, some even reaching clinical trials and being commercialized as “anticancer” drugs. This review aimed to describe these depsipeptides, their reported amino acid sequences, determined structure, and the specific mechanism by which they target tumor cells including apoptosis, oncosis, and elastase inhibition, among others. Furthermore, we have delved into state-of-the-art in vivo and clinical trials, current methods for purification and synthesis, and the recognized disadvantages of these molecules. The information collated in this review can help researchers decide whether these molecules should be incorporated into functional foods in the near future. MDPI 2023-01-09 /pmc/articles/PMC9864405/ /pubmed/36677728 http://dx.doi.org/10.3390/molecules28020670 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Trinidad-Calderón, Plinio A.
Varela-Chinchilla, Carlos Daniel
García-Lara, Silverio
Depsipeptides Targeting Tumor Cells: Milestones from In Vitro to Clinical Trials
title Depsipeptides Targeting Tumor Cells: Milestones from In Vitro to Clinical Trials
title_full Depsipeptides Targeting Tumor Cells: Milestones from In Vitro to Clinical Trials
title_fullStr Depsipeptides Targeting Tumor Cells: Milestones from In Vitro to Clinical Trials
title_full_unstemmed Depsipeptides Targeting Tumor Cells: Milestones from In Vitro to Clinical Trials
title_short Depsipeptides Targeting Tumor Cells: Milestones from In Vitro to Clinical Trials
title_sort depsipeptides targeting tumor cells: milestones from in vitro to clinical trials
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864405/
https://www.ncbi.nlm.nih.gov/pubmed/36677728
http://dx.doi.org/10.3390/molecules28020670
work_keys_str_mv AT trinidadcalderonplinioa depsipeptidestargetingtumorcellsmilestonesfrominvitrotoclinicaltrials
AT varelachinchillacarlosdaniel depsipeptidestargetingtumorcellsmilestonesfrominvitrotoclinicaltrials
AT garcialarasilverio depsipeptidestargetingtumorcellsmilestonesfrominvitrotoclinicaltrials